Oral and Subcutaneous Anticancer Therapy Training Course for Non-physician Healthcare Professionals: a Survey Evaluating the Relevance of its Content and its Implications in the Practice of Cancer Care

Evgenii Shumilov(University Hospital Münster), Florian Kaiser(University of Applied Sciences Landshut), Xenia Schulz(University of Applied Sciences Landshut), Gamze Damnali, Ulrich Kaiser(University of Applied Sciences Landshut), Ulrike Bacher(Hattiesburg Clinic), Ursula Vehling‐Kaiser(University of Applied Sciences Landshut)

Journal of Cancer Education

June 25, 2020

10.1007/s13187-020-01794-2

Cited by 1

Related Papers

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2014|1.7k

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

|The Lancet Oncology|2016|417

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients

|Blood|2007|410

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

|The Lancet Oncology|2015|402